I am so pleased to announce the initiation of a new clinical program with the first-in-human phase 1 clinical trial of our LRRK2 inhibitor, HT-4253, which we are developing for the early intervention of APOE4 homozygous individuals at high risk for developing Alzheimer's Disease. We will first establish the drug's safety profile and then move into a unique clinical trial in these genetically defined high-risk APOE4 homozygous individuals. I will make sure to keep everyone up-to-date on our progress. https://lnkd.in/ggnmiBjv #APOE4 # Alzheimer's Disease
